The purpose of this research study is to see how the brain changes in patients receiving chemotherapy (cytotoxic drug) treatment for colon or rectal cancer at Parkview Cancer Institute. This information will be used to identify helpful tests to diagnose individuals at risk for developing difficulties with thinking and memory due to their cancer treatments.
Signed written informed consent must be obtained and documented according to International Conference on Harmonisation (ICH)- Good Clinical Practice (GCP), the local regulatory requirements, and permission to use private health information in accordance with the Health Insurance Portability and Accountability Act (HIPAA) prior to study-specific screening procedures. Must be able to provide study-specific informed consent prior to study entry.
A histologically-confirmed colorectal tumor
Patients who will be treated with cytotoxic chemotherapies including Capecitabine, Oxaliplatin, 5 fluorouracil, and Irinotecan are eligible.
Patients must not have received cytotoxic chemotherapy previous to enrollment.
Prior administration of anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents
Patients having mental incompetence as assessed by study PI, which would hinder completion of the surveys
Pregnant or breastfeeding
Any known brain metastases
Ambulatory colorectal oncology patients undergoing cytotoxic therapy.
Cohort
Prospective
Not listed
Survey
FACT-Cog V3
The Proteome Profiler Human XL Cytokine Array Kit (https://www.rndsystems.com/products/proteome-profiler-human-xl-cytokine-array-kit_ary022b)
This panel of plasma factors will be will be used to detect protein from the blood of patients throughout and after chemotherapy treatment.
Click on the lead sponsor to view all of their trials.
